One of these compounds, the NO-stimulator riociguat (Adempas), is currently applied clinically in pulmonary hypertension.5 Although hemodynamically reasonable, the use of these compounds in clinical trials of heart failure has been hampered by extensive systemic hypotensive effects of both stimulators6 and particularly activators.7, -9 However, the recently published VICTORIA study found a clinical benefit for the sGC stimulator vericiguat in patients with heart failure with reduced ejection fraction already on established guideline heart failure therapy.10 The gene discussed is SGCB; the disease is pulmonary hypertension.